1. Introduction {#s0005}
===============

Circular RNAs (circRNAs) are a class of novel RNAs that are expressed across the eukaryotic tree of life ([@bb0120], [@bb0285]). CircRNAs can be formed by back-splicing, which is a non-canonical process in RNA splicing ([@bb0120]). Although little is known regarding the exact mechanisms of circRNA biogenesis, some factors have been shown to regulate this process, such as flank intronic sequences ([@bb0185], [@bb0280], [@bb0310]) and RNA-binding proteins ([@bb0020], [@bb0240]). CircRNAs have been revealed to perform several important functions, including microRNA (miRNA) sponges ([@bb0110], [@bb0200]), alternative RNA splicing regulation ([@bb0050]), and transcriptional regulation of the parental gene ([@bb0175]). Recent studies have also suggested that some circRNAs can be translated in a cap-independent translation manner and function in myogenesis ([@bb0160], [@bb0230], [@bb0295]). Furthermore, circRNAs have been found to be differentially expressed across human tissues and cell types ([@bb0105], [@bb0260]) and extraordinarily enriched in the mammalian brain ([@bb0255], [@bb0300]). Although circRNAs are generally expressed at low levels ([@bb0040], [@bb0105]), some circRNAs are expressed more abundantly than their linear counterparts ([@bb0260]). Dynamic circRNA profiles are related to neurogenesis ([@bb0255]), mouse brain development ([@bb0300]), and human epithelial-mesenchymal transition ([@bb0045]). Aberrant expression of many circRNAs has been implicated in several human diseases, including cancers ([@bb0210]), neurodegenerative diseases ([@bb0145]), and some hematological malignancies ([@bb0030]). Notably, circRNAs are enriched and stable in whole blood ([@bb0205]), platelets ([@bb0010]), and exosomes ([@bb0170]). These features make circRNAs in human peripheral blood good candidates for diagnostic or prognostic biomarkers of human diseases.

Tuberculosis (TB) is an infectious disease caused by *Mycobacterium tuberculosis* ([@bb0225]). Although TB incidence, prevalence, and mortality have decreased since 2000, the World Health Organization (WHO) estimated that there were 1.5 million TB-associated deaths and 10.5 million new TB cases worldwide in 2015 ([@bb0290]). In particular, China has the third largest number of TB cases in the world, which is approximately 10% of the world total ([@bb0290]). To achieve better TB management, some novel diagnostic methods, especially a rapid, low-cost, and non-sputum-based test, are required to screen active TB patients at the primary-care level ([@bb0290]). Recently, several studies have developed blood transcriptomic signatures to distinguish active pulmonary TB patients from other pulmonary disease cohorts and healthy controls ([@bb0025], [@bb0235], [@bb0250], [@bb0265]) and predicted the risk of developing active TB ([@bb0305]). However, the expression of mRNA transcripts in peripheral blood can be obscured by blood collection procedures, which may slow down the process of their clinical applications ([@bb0075]). As an alternative to blood transcriptional signatures, Liu et al. also developed a method of quantifying the circulating *Mycobacterium tuberculosis* antigen peptides for active TB diagnosis and treatment monitoring ([@bb0190]). Compared with blood transcriptional signatures, the amount of circulating bacterial antigens in blood could be too low to be detected at the early stage of disease ([@bb0005]). Therefore, new markers in the peripheral blood are needed to facilitate the early diagnosis and treatment of active pulmonary TB.

In this study, we investigated the potential of using circRNAs in peripheral blood mononuclear cells (PBMCs) as biomarkers for pulmonary TB diagnosis. First, we characterized circRNA expression profiles in human PBMCs using ribosomal RNA-depleted (rRNA-depleted) RNA-seq and circRNA expression microarrays. We compared the circRNA repertoire in PBMCs with that in whole blood and other blood components, such as platelets and red blood cells. Under the assumption that the function of a given circRNA could be associated with the known function of its parental gene, we performed a pathway-based analysis to identify the PBMC circRNAs that are dysregulated in TB patients. Compared with host linear transcripts, the circRNAs within several Kyoto Encyclopedia of Genes and Genomes (KEGG) ([@bb0130]) physiological pathways were observed to be disproportionately upregulated in active TB patients. Based on these differentially expressed circRNAs, we developed a PBMC circRNA-based molecular signature that can differentiate active TB patients from healthy controls. Finally, we validated the performance of our circRNA signature in an independent cohort using quantitative real-time PCR (qRT-PCR). Our results suggest the feasibility of using PBMC circRNAs as molecular markers to diagnose active TB. [Fig. 1](#f0005){ref-type="fig"} provides an overview of the experimental design.Fig. 1The experimental scheme of the study. The discovery cohort was composed of two TB patients and two age- and gender-matched healthy controls: one young male case-control pair and one senior female case-control pair. PBMC circRNA expression in the discovery cohort was profiled by both rRNA-depleted RNA-seq and a circRNA expression microarray. We aggregated circRNAs into pathway-level mechanisms using KEGG pathway definitions. Pathways with significant circRNA dysregulation were prioritized by performing a paired Wilcoxon signed-rank test between paired control and TB samples. A molecular signature was developed based on the dysregulated circRNAs within the prioritized pathways. This circRNA signature was further validated by qRT-PCR in a validation cohort with 11 healthy controls and 10 TB patients.Fig. 1

2. Materials and Methods {#s0010}
========================

2.1. Human Subjects {#s0015}
-------------------

This study was approved by the Ethics Committee of Bengbu Medical College, with written informed consent obtained from all subjects. This was conformed to standards indicated by the Declaration of Helsinki. The diagnosis of active pulmonary TB was based on established international guidelines ([@bb0165]). Subjects with other concurrent infectious diseases were excluded. All the subjects investigated were of Chinese Han descent. The discovery cohort included two subjects with active pulmonary TB and two age- and gender-matched healthy controls: one young male case-control pair and one senior female case-control pair (Supplementary Table S1). The validation cohort consisted of 10 TB patients and 11 healthy controls, with no significant difference in age and gender between the cases and controls (Supplementary Table S2). The TB patients in the discovery and validation cohorts were recruited from the First Hospital of Huainan City and the Infectious Disease Hospital of Bengbu City, respectively. The healthy controls were recruited from Bengbu Medical College. Several clinical TB status indicators of each individual in the validation cohort, including the number of cavities, diameter of the largest cavities, and sputum smear grade were obtained.

2.2. Cell Purification, RNA Isolation and circRNA Expression Profiling {#s0020}
----------------------------------------------------------------------

PBMCs were collected from all subjects in the discovery and validation cohorts. To profile PBMC circRNA expression in the discovery cohort, we constructed ribosomal RNA (rRNA)-depleted RNA-seq libraries using PBMC total RNA from each person in the discovery cohort. The expression of PBMC circRNAs in the discovery cohort was also profiled using the CapitalBio Technology Human CircRNA Array v2 (CapitalBio Technology, Beijing, China). The experimental details of cell purification, RNA isolation, RNA-seq library preparation and sequencing, and circRNA microarray expression profiling were available in Supplementary Methods. Raw sequencing reads were available at the NCBI Short Read Archive (SRA) ([@bb0140]) under the accession number SRP115429, and circRNA microarray data were deposited at the NCBI Gene Expression Omnibus (GEO) ([@bb0080]) under the accession number GSE103188.

2.3. RNA-seq Data of Whole Blood and Other Blood Components {#s0025}
-----------------------------------------------------------

To compare the circRNA repertoire in PBMCs with that in whole blood and other blood components, we collected several RNA-seq datasets from public databases, which included six samples of human whole blood ([@bb0205]), three samples of human blood platelets ([@bb0135]), and one sample of human red blood cells (RBCs) ([@bb0010]) (Supplementary Table S3). All these samples were sequenced using rRNA-depleted RNA-seq libraries in their original studies ([@bb0010], [@bb0135], [@bb0205]). We downloaded the raw RNA-seq reads of these samples from SRA ([@bb0140]).

2.4. Identification and Expression Quantification of circRNAs From RNA-seq Data {#s0030}
-------------------------------------------------------------------------------

The raw RNA-seq reads were filtered by removing adaptor sequences, contamination, and low-quality reads. To assure the sequencing performance and library quality, we used *RNA-SeQC* ([@bb0060]) to assess the data quality of each RNA-seq dataset. For each sample, we identified all putative circRNAs using *CIRI* ([@bb0090]) with default parameter settings. After circRNA identification, we quantified the expression values of all identified circular transcripts and known linear transcripts in the *Ensembl* ([@bb0055]) human gene annotation (release 87) using our recent developed tool, *Sailfish-cir* ([@bb0180]), with default settings. For each host gene, the transcripts per million (*TPM*) values of both linear and circular transcripts were recorded. These circRNA identification and quantification procedures were performed for both our PBMC and the public (the other blood component) RNA-seq raw data. The normalized *TPM* values of circRNAs were used to explore the global differences of circRNA repertoire among human blood components.

2.5. Inferring Differentially Expressed Pathways and circRNAs {#s0035}
-------------------------------------------------------------

To discover PBMC circRNA signature in differentiating TB patients from healthy controls, we identified differentially expressed pathways and circRNAs from human PBMC RNA-seq and microarray data, respectively. First, we aggregated circRNAs into pathway-level mechanisms using KEGG annotations. A paired *Wilcoxon* signed-rank test was performed to compare the paired circRNA expression profiles restricted to a given KEGG pathway between paired control and TB samples ([@bb0095]). The pathways with an adjusted *P*-value \< 0.05 after *Benjamini* and *Hochberg* correction were deemed differentially expressed. Next, the *edgeR* ([@bb0245]) and *SAM* ([@bb0270]) algorithms were used to identify the differentially expressed circRNAs. For the RNA-seq data, only the circRNAs with a reads-per-million value \> 5 in at least two samples were included. We further excluded the circRNAs with average junction read counts \< 5. For the microarray data, only the circRNAs without absent calls were retained. We limited our analysis to the circRNAs with unique circBase ([@bb0100]) annotation and removed the circRNAs on chromosomes X and Y to avoid the potential confounding sex factor. The circRNAs with a false discovery rate (FDR) \< 5% were deemed differentially expressed.

2.6. qRT-PCR Validation {#s0040}
-----------------------

We validated the performance of the dysregulated PBMC circRNAs in differentiating active pulmonary TB patients from healthy controls in an independent validation cohort. qRT-PCRs were performed to quantify the expression of the prioritized PBMC circRNAs. We designed divergent primers for the selected circRNAs using *CircInteractome* ([@bb0070]) (Supplementary Table S4). qRT-PCRs were performed on a QuantStudio 3 Real-Time PCR System (Thermo Fisher Scientific, Massachusetts, USA) using a SYBR Green Real Master Mix with Rox (Tiangen, Beijing, China). The housekeeping gene, β-actin, was used as an internal control. The comparative CT (2^− ΔΔCT^) method was used to obtain the fold change of circRNA expression levels, and Student\'s *t*-test was used to test its statistical significance.

2.7. CircRNA-based TB Index {#s0045}
---------------------------

We applied a scoring method used in our previous study to assign each human subject a TB index ([@bb0235]): $I = \sum\limits_{i = 1}^{n}\left( {e_{i} - \mu_{i}} \right)/\tau_{i}$. Here, *I* is the circRNA-based TB index; *n* is the number of circRNAs; *e*~*i*~ denotes the expression level of circRNA *i*; and μ~i~ and *τ*~*i*~ are the mean and standard deviation of the expression of circRNA *i* across all samples, respectively. A higher TB index implies a higher likelihood of active TB.

3. Results {#s0050}
==========

3.1. Landscape of circRNA Expression in Human PBMCs {#s0055}
---------------------------------------------------

Previous studies have suggested that circRNAs are enriched in human peripheral whole blood ([@bb0205]), platelets ([@bb0010]), and exosomes ([@bb0170]), and circRNAs in whole blood and blood components could be used as biomarker molecules. To explore whether PBMC circRNAs are potential molecular markers as well, we first investigated the landscape of expressed circular transcripts and their expression pattern in human PBMCs. We sequenced four rRNA-depleted RNA-seq libraries of human PBMC samples in the discovery cohort (Supplementary Table S3). The expression of both mRNAs and circRNAs was simultaneously quantified by *Sailfish-cir* ([@bb0180]). In total, 5175 parental genes were found to express circular transcripts in these four human PBMC samples, among which the circular transcripts of 131 parental genes were highly expressed with an average *TPM* \> 100.

We also analyzed the rRNA-depleted RNA-seq data of human whole blood, platelets, and RBCs (Supplementary Table S3). The PBMC circRNA repertoire was then compared with the circRNAs identified in whole blood, platelets, and RBCs. We observed that the number of parental genes with circular transcripts was comparable among PBMCs, platelets, and whole blood ([Fig. 2](#f0010){ref-type="fig"}a). There were 3739 host genes commonly expressing circular transcripts in PBMCs, platelets, and whole blood ([Fig. 2](#f0010){ref-type="fig"}a). The circRNA expression level in PBMCs was significantly higher than that in whole blood and RBCs (*t*-test: *P* \< 10^− 10^) but lower than that in platelets (*t*-test: *P* \< 10^− 10^) ([Fig. 2](#f0010){ref-type="fig"}b). In comparison, human RBCs had the least number of identified circRNAs ([Fig. 2](#f0010){ref-type="fig"}a) and the lowest level of circRNA expression ([Fig. 2](#f0010){ref-type="fig"}b). These results suggest that circRNAs are widely expressed in human PBMCs. Furthermore, the expression of a substantial number of circular transcripts was high enough to be detected, which ensures that circRNAs in PBMCs, like those in whole blood and platelets, meet the essential requirements as molecular markers.Fig. 2Landscape of PBMC circRNA expression. (a) A Venn diagram of the parental genes with circRNA transcripts among PBMCs, platelets, RBCs, and whole blood. (b) Distribution of log~2~-transformed *TPM* values of circular transcripts in PBMCs, platelets, RBCs, and whole blood. (c) The fraction of RNA-seq reads from coding linear, non-coding linear, and circular transcripts. (d) The cumulative distribution of *TPM* values of circular transcripts. A significantly increased circRNA *TPM* was observed in the TB patients compared with the healthy controls. The *P*-values were computed by the Kolmogorov-Smirnov test.Fig. 2

3.2. Pathway-based Analysis of PBMC circRNA Dysregulation in TB Using RNA-seq {#s0060}
-----------------------------------------------------------------------------

Next, we investigated the difference in PBMC circRNA expression between TB patients and healthy controls in the discovery cohort. We observed that the RNA-seq reads fraction of circRNA transcripts in the PBMC transcriptome was consistently increased in both young and senior TB patients compared with healthy controls ([Fig. 2](#f0010){ref-type="fig"}c). The circRNA *TPM* of the TB patients was significantly higher than that of the healthy controls (*Kolmogorov-Smirnov* test: *P* \< 10^− 10^) ([Fig. 2](#f0010){ref-type="fig"}d).

Given the broad differences in PBMC circRNA expression between TB patients and healthy controls, we performed a pathway-based paired-sample analysis to identify the dysregulated biological processes by pooling circRNAs into host gene pathways. In this analysis, we assumed that the function of a given circRNA could be associated with the known function of its parental gene, as circRNAs can potentially cis-regulate their corresponding host genes ([@bb0040], [@bb0175], [@bb0275]). Briefly, a paired Wilcoxon signed-rank test was applied to compare the paired circRNA expression profiles restricted to a given KEGG pathway between healthy controls and TB patients for the young and senior pairs, respectively ([@bb0095]). Unlike conventional transcriptomic approaches that have been developed to uncover molecular signatures across a large population of human subjects, this approach enables discovery of dysregulated pathways unique to individual case-control pairs and highlights both the individuality and commonality of a clinical trait ([@bb0095]).

In total, five KEGG pathways were found to be commonly upregulated (adjusted *P* \< 0.05) regarding circRNA expression in both young and senior TB patients ([Fig. 3](#f0015){ref-type="fig"}a), including "Cytokine-cytokine receptor interaction", "Chemokine signaling pathway", "Fc gamma R-mediated phagocytosis", "Neurotrophin signaling pathway", and "Bacterial invasion of epithelial cells" ([Fig. 3](#f0015){ref-type="fig"}b and Supplementary Table S5). The *Z*-score of the Wilcoxon test was significantly and positively correlated between the young and senior TB control pairs (*Spearman*\'s rank correlation test: *ρ* = 0.506 and *P* \< 10^− 10^) ([Fig. 3](#f0015){ref-type="fig"}a), which reflects the commonality in circRNA dysregulation patterns between young and senior TB patients.Fig. 3The KEGG pathways enriched by upregulated circRNAs. A paired Wilcoxon test was applied to identify the KEGG pathways enriched by dysregulated circRNAs in young and senior TB patients. (a) The correlation in *Z*-scores (computed by a paired Wilcoxon test) between young and senior case-control pairs. Each dot represents one KEGG pathway. The red points stand for the pathways with circular transcripts commonly upregulated in both young and senior TB patients. (b) Paired comparison of circRNA expression in the five prioritized KEGG pathways. (c) Comparison of the fraction of circRNA reads in the five pathways between healthy controls and TB patients.Fig. 3

To understand whether the alteration of circRNA abundance in the five prioritized pathways is simply a function of the host gene dysregulation, we computed the fraction of circRNA reads over the total read count (reads from both circular and linear transcripts) for each host gene. We found that the fraction of circRNA reads was significantly higher in TB patients than in healthy controls in all five pathways (paired Wilcoxon test: *P* \< 0.05) ([Fig. 3](#f0015){ref-type="fig"}c), which suggests that circRNA expression is somewhat independent of host linear transcripts and, at least to a certain extent, the circRNA dysregulation in TB PBMCs is not a secondary consequence of the host gene expression.

3.3. Technical Validation of the Prioritized Pathways Using a circRNA Microarray {#s0065}
--------------------------------------------------------------------------------

To verify that the above findings were not caused by potential technical bias introduced by RNA-seq procedures ([@bb0150], [@bb0320]), we further performed circRNA microarray analysis of the same PBMC RNA samples treated by RNase R ([@bb0125]). The CapitalBio Technology Human CircRNA Array v2 (4 × 180K) was used to quantify circRNA expression. As indicated in [Fig. 4](#f0020){ref-type="fig"}, the microarray data perfectly mirrored our findings from the RNA-seq analysis. The five prioritized pathways were consistently upregulated with respect to circRNA expression (paired Wilcoxon test: *P* \< 0.05) ([Fig. 4](#f0020){ref-type="fig"}). These results confirmed that the dysregulated pathways we prioritized from TB PBMC circRNAs were independent of the circRNA detection and quantification methods.Fig. 4Technical validation of the five prioritized KEGG pathways using a circRNA expression microarray. Total RNA was treated with RNase R to remove linear transcripts and then subject to microarray hybridization.Fig. 4

3.4. Classification Power of PBMC circRNA Expression in TB {#s0070}
----------------------------------------------------------

Finally, we explored the predictive power of PBMC circRNA expression in differentiating TB patients from a healthy population. We further explored the RNA-seq and microarray data to compare the expression of individual circRNAs within the five prioritized pathways between TB patients and healthy controls. In total, seven circRNAs with unique circBase annotations were identified to be commonly upregulated in TB PBMCs in both the RNA-seq and microarray data (see *Methods* for details), which was designated the 7-circRNA signature ([Table 1](#t0005){ref-type="table"} and [Fig. 5](#f0025){ref-type="fig"}a).Fig. 5The 7-circRNA signature. (a) Expression heatmap of the circRNAs within the 7-circRNA signature in the discovery cohort. The expression measured by both RNA-seq and circRNA microarray is displayed. (b) Comparison of the expression levels of the 7-circRNA signature between the healthy controls and TB patients in the validation cohort. The error bars represent the standard error of the mean. (c) Principal component analysis of the 7-circRNA signature. PC1: the first principal component; PC2: the second principal component. (d) Comparison of the circRNA-based TB index between the healthy controls and TB patients in the validation cohort. (e) The ROC curve of the TB index in distinguishing TB patients from healthy controls. The light blue area indicates the confidence interval of the ROC curve.Fig. 5Table 1The 7-circRNA signature.Table 1circBase IDGenomic positionStrandLengthGeneAssociated KEGG pathwayhsa_circ_0000414chr12:66597490-66605377+455*IRAK3*Neurotrophin signaling pathwayhsa_circ_0000681chr16:23999828-24046868+324*PRKCB*Chemokine signaling pathway; Fc gamma R-mediated phagocytosishsa_circ_0002113chr21:34793786-34805178+673*IFNGR2*Cytokine-cytokine receptor interactionhsa_circ_0002362chr2:9458652-9468040+341*ASAP2*Fc gamma R-mediated phagocytosishsa_circ_0002908chr8:141840570-141874498−286*PTK2*Chemokine signaling pathway; Bacterial invasion of epithelial cellshsa_circ_0008797chr3:119582265-119624699−420*GSK3B*Chemokine signaling pathway; Neurotrophin signaling pathwayhsa_circ_0063179chr22:37328806-37330036+303*CSF2RB*Cytokine-cytokine receptor interaction

The 7-circRNA signature was then assessed in the validation cohort with 11 healthy controls and 10 TB patients. qRT-PCR was used to quantify the expression of each individual circRNA. Elevated expression was observed for all the prioritized circRNAs (*t*-test: *P* \< 0.05), except for hsa_circ_0000414 (*t*-test: *P* = 0.171) ([Fig. 5](#f0025){ref-type="fig"}b). Principal component analysis indicated that the 7-circRNA signature differentiated TB patients from healthy controls in the validation cohorts ([Fig. 5](#f0025){ref-type="fig"}c). To systematically evaluate the classification power of the 7-circRNA signature, a circRNA-based TB index was assigned to each subject (see [Methods](#s0010){ref-type="sec"} for details). The TB index is a linear combination of the 7-circRNA expression values, and a higher TB index implies a higher likelihood of TB. We found that the 7-circRNA-based TB index was significantly higher in TB patients than in healthy controls (*t*-test: *P* = 0.001) ([Fig. 5](#f0025){ref-type="fig"}d). The area under the receiver operating characteristic (ROC) curve (*AUC*) was 0.946 ([Fig. 5](#f0025){ref-type="fig"}e). We further tested whether the predictive power of the circRNA-based TB index was dependent on standard TB clinical indicators, including number of cavities, diameter of the largest cavities, and sputum smear grade. Multivariate logistic regression indicated that the 7-circRNA-based TB index was the most significant predictor of TB status (*P* = 0.038) (Supplementary Table S6). This suggests that circRNA expression information adds independent value to TB diagnosis. We also investigated the correlation between the 7-circRNA-based TB index and the above clinical indicators. However, no significant correlation was observed (Supplementary Table S7), which may be partly due to the limited sample size in the validation cohort.

4. Discussion {#s0075}
=============

In this study, we explored the potential of using human PBMC circRNAs as the molecular markers to diagnose active pulmonary TB. Due to the remarkable stability of circRNAs ([@bb0085]), several groups have already investigated circRNA expression in easily accessible human body fluids to determine the potential of circRNAs as biomarkers ([@bb0010], [@bb0015], [@bb0170], [@bb0205]). For example, Memczak et al. reported the detection of thousands of circRNAs and high expression of hundreds of circRNAs in human peripheral whole blood ([@bb0205]). Some comprehensive analysis further revealed stable and enriched circRNAs in some human blood components, including erythrocytes ([@bb0010]), platelets ([@bb0010]), and exosomes ([@bb0170]). As an alternative to using human peripheral blood, Bahn et al. identified \> 400 circRNAs in cell-free saliva samples ([@bb0015]). Unlike the above studies, we investigated the circRNA repertoire in a different blood component, human PBMCs. PBMCs contain any peripheral blood cell with a round nucleus, including monocytes and lymphocytes. In our results, we showed wide and abundant circRNA expression in human PBMCs, which is comparable to the circRNA landscapes in human whole blood, RBCs, and platelets ([Fig. 2](#f0010){ref-type="fig"}A and B). This result complements previous observations by [@bb0010], who found that circular transcripts are enriched in human platelets, with a 17- to 188-fold change relative to nucleated tissues, which is a common signature of anucleate cells ([@bb0010]). Our study suggests that, similar to anucleate cells, the magnitude of PBMC circRNA expression may also be higher than that of nucleated tissues and other nucleate cells. This is potentially an exciting feature of human PBMCs, as it implies that circRNAs in human PBMCs may be used as liquid biomarker molecules for human diseases.

Compared with previous blood circRNA studies ([@bb0010], [@bb0170], [@bb0205]), we pushed several steps forward in investigating the potential of using blood circRNAs as diagnostic markers of human diseases. In addition to the exploration of the circRNA repertoire in human PBMCs, we investigated several key questions in biomarker development, including the differential expression of circRNAs between cases and controls and the development and validation of a circRNA signature. We showed that the magnitude of PBMC circRNAs in TB patients was significantly higher than that of the paired healthy controls ([Fig. 2](#f0010){ref-type="fig"}C and D). A KEGG pathway-based paired-sample analysis identified several dysregulated biological processes in human PBMCs, including "Cytokine-cytokine receptor interaction", "Chemokine signaling pathway", "Fc gamma R-mediated phagocytosis", "Neurotrophin signaling pathway", and "Bacterial invasion of epithelial cells" ([Fig. 3](#f0015){ref-type="fig"}b and Supplementary Table S5). Most of these dysregulated pathways are relevant to the occurrence and development of TB. For example, cytokines, chemokines, and their receptors are critical factors in achieving an optimal balance between innate and adaptive immune cells, which can determine the progression or outcome of *Mycobacterium tuberculosis* infection ([@bb0065], [@bb0220]), while Fc gamma R may play a role in Fc-mediated Ab effector functions in pathogen clearance ([@bb0195]). Based on these dysregulated pathways, we prioritized seven differentially expressed PBMC circRNAs in TB patients ([Fig. 5](#f0025){ref-type="fig"}a), yielding a 7-circRNA TB molecular signature. We further validated the predictive power of the 7-circRNA signature to differentiate TB patients from healthy controls in an independent cohort ([Fig. 5](#f0025){ref-type="fig"}b). Our results strongly suggest that PBMC circRNAs are promising biomarkers to differentiate active TB patients from healthy controls ([Fig. 5](#f0025){ref-type="fig"}c--e). However, more thorough studies are needed to test the performance of our 7-circRNA signature as a TB diagnostic biomarker. Due to the limited sample size of the discovery cohort, we used a pathway-based algorithm to control false discovery rate of the prioritized circRNAs. This method potentially overlooks the circRNAs without pathway annotation. In future study, unbiased screening of circRNAs at the whole transcriptomic level in a large cohort will be highly helpful. Moreover, some other diseases with similar clinical phenotypes, such as lung cancers, pneumonias, and pulmonary sarcoidosis, may confound TB diagnosis in clinical application. In future studies, these diseases should be considered to justify the signature\'s diagnostic specificity when developing TB-specific biomarkers.

Although several studies have developed transcriptomic signatures to diagnose active pulmonary TB ([@bb0025], [@bb0235], [@bb0250], [@bb0265]) or predict the risk of developing active TB ([@bb0305]), a PBMC-based circRNA signature is still meaningful with practical significance in TB management. In previous studies, mRNA transcripts in peripheral blood were used as marker molecules ([@bb0025], [@bb0235], [@bb0250], [@bb0265]). However, mRNA expression-based gene signatures do not always deliver accurate information with reproducible and robust performance, which is especially important when translating the signatures into clinic diagnostics ([@bb0035]). This is even more obvious when using peripheral blood as the sample source, as standard blood collection procedures cause rapid changes in the mRNA profiles of hematopoietic cells ([@bb0075]). Given the higher stability of circRNAs ([@bb0085]), circRNAs are ideal candidate molecules to overcome this shortcoming. Many circRNA biomarkers have been introduced to manage human cancers ([@bb0210]). However, most of these circRNA biomarkers were identified from tissue samples. Because tissue samples are impossible to collect in clinical practice of infectious disease management, such as TB, a tissue-based circRNA biomarker is not applicable in TB diagnosis. In a recent study, a peripheral blood circRNA, hsa_circ_0124644, was proposed to diagnose coronary artery disease ([@bb0315]). However, gene expression measurements in human peripheral whole blood are more variable among individuals than several blood components, including PBMCs, lymphoblastoid cell lines, and CD19- and CD20-specific B-cell subsets ([@bb0215]). Because monocytes ([@bb0155]) and lymphocytes ([@bb0115]) in human PBMCs are both relevant to TB, a PBMC circRNA signature is able to directly reflect the host responses to infection of *Mycobacterium tuberculosis*. Compared with circRNAs in exosomes or platelets, the TB signature based on PBMC circRNAs should be much stronger and more easily detected. In addition, PBMC circRNA-based TB index may add additional values to existing clinical tests in TB diagnosis, such as chest X-ray and sputum smear (Supplementary Table S6). Given the advantage of high accuracy, easy sample acquisition and short turnaround time, PBMC circRNA expression signature has the potential to complement current clinical settings in diagnosing active TB and monitoring TB treatment outcomes.

In conclusion, we suggested that PBMC circRNAs are potentially reliable marker molecules to diagnose active TB, which may have translational implications in TB management.
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